Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: tool dude who wrote (123821)	12/5/2003 5:51:39 PM
From: Taki	Respond to of 150070

RDXM says?.11x.118.ZE high of ZE day.Volume keeps going crazy the last four days. Message 19535391

To: tool dude who wrote (123821)	12/5/2003 6:01:06 PM
From: Taki	Respond to of 150070

HTDS .085x.087.It made my call of .10 today.WOW.Was .05 then, and first call .013.Still hold a few for next week. Message 19560274 Message 19543508

To: tool dude who wrote (123821)	12/5/2003 6:08:20 PM
From: StocksDATsoar	Read Replies (1) \| Respond to of 150070

I DON'T GET THIS NEW RELEASE..DIDN'T CHUCK T AND THE ROY FAX OUT HTDS? THEY SURE DID AND LOOK @ THE CONTENT OF THIS NR (BSNS WIRE) Hard to Treat Diseases Incorporated - HTDS - Request to Sharehold ers and Interested Investors Hard to Treat Diseases Incorporated - HTDS - Request to Shareholders and Interes ed Investors Health/Medical Writers / Business Editors DELRAY BEACH, Fla.--(BUSINESS WIRE)--HTDS-- Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) - It has come to the attention of Hard to Treat Diseases Incorporated that unrelated third party individuals or entities are releasing information about the Company through mass fax and/or email blasts. The Company is moving ahead with the testing of Tubercin. The Company urges all investors and potential investors to review the company's press releases and web site rather than relying on non-Company disseminated information. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccaharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. KEYWORD: FLORIDA INDUSTRY KEYWORD: BANKING MEDICAL PHARMACEUTICAL MEDICAL PRODUCT SOURCE: Hard to Treat Diseases Incorporated CONTACT INFORMATION: Hard to Treat Diseases Incorporated, Delray Beach Colm King, 561/272-6900 * end of story *